The recent approval of subcutaneous nivolumab injection (Opdivo Qvantig) marks the next step in the evolution of cancer therapy—and one that promises new solutions for patients and cancer ...

On February 28, Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents assigned to Bristol-Myers Squibb Co. (“BMS”).

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption ...

The Company added five assets to its industry-leading biosimilars pipeline, which now comprises 28 molecules. Pembrolizumab and nivolumab, two oncology assets addressing more than USD 40 billion ...

The Company added five assets to its industry-leading biosimilars pipeline, which now comprises 28 molecules. Pembrolizumab and nivolumab, two oncology assets addressing more than USD 40 billion of ...

driven by double-digit growth in biosimilars, both in the fourth quarter and full year, benefitting from recent launches and base-business momentum Operating income of USD 307 million, up by 5% in ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...

4 The CHMP also recommended new indications for nivolumab (Opdivo) and ipilimumab (Yervoy), both reference products with several biosimilars in development. Should they be approved, the new indication ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the Food and Drug Administration. HealthDay News — The U.S. Food and Drug ...